The commercialization of BCMA-targeted therapies like Abecma, Carvykti, and Blenrep marks a major advancement in the treatment of multiple myeloma. As more companies enter the market and new therapies emerge, the BCMA therapy landscape will continue to evolve, offering patients more effect